Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Israel has clear objectives south of Litani River, but will face difficult choices further north - 2Creative Tech Contraptions That Will Work on Your Life
- 3EU chief urges Iran to free imprisoned protesters, lift internet ban
- 4Pick Your #1 game to observe
- 5Starfront Observatories: A haven for distant stargazers
- Figure out How to Track and Anticipate Future Cd Rates
- Posts falsely claim Malaysian minister to relocate public hospital for temple
- Online business Stages for Little Retailers
- Vote in favor of the juice that you love for its medical advantages!
- Magnetic fossils may reveal ancient creature's internal 'GPS system'
- Colorado residents face earliest water restrictions ever — a harbinger of worse to come
- Gartex Texprocess India to showcase innovations across textile ecosystem
- Red Crescent: More than 100,000 civilian structures damaged in Iran
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
